Publication Name	World Journal of Clinical Oncology
Manuscript ID	77472
Country	Spain

Received	2022-05-09 01:28
Peer-Review Started	2022-05-09 01:30
First Decision by Editorial Office Director	2022-06-16 10:43
Return for Revision	2022-06-16 10:43
Revised	2022-07-06 22:52
Publication Fee Transferred
Second Decision by Editor	2022-08-29 03:59
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-08-31 04:31
Articles in Press	2022-08-31 04:31
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-09-14 06:40
Publish the Manuscript Online	2022-09-22 06:32

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast
Manuscript Source	Unsolicited Manuscript
All Author List	Carlos Aguado, Unai Jiménez Maestre and Xabier Mielgo-Rubio
Funding Agency and Grant Number
Corresponding Author	Carlos Aguado, MD, Consultant Physician-Scientist, Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Calle del Prof Martín Lagos, Madrid 28040, Spain. carlos.aguado84@gmail.com
Key Words	Neoadjuvant; Immunotherapy; NSCLC; Perioperative; Checkmate-816; nivolumab; Chemo-immunotherapy
Core Tip	Recent data from a phase 3 trial show that the addition of immunotherapy to neoadjuvant chemotherapy in patients with non-small-cell lung cancer (NSCLC) improves pathologic complete response and event-free survival. This is the first positive phase 3 trial in this setting, although several other phase 3 studies are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC. We describe the results of the CheckMate-816 phase 3 trial, which found that neoadjuvant chemoimmunotherapy was superior to chemotherapy alone. We also briefly review the main phase 3 studies currently underway to evaluate the role of immunotherapy in the perioperative setting of NSCLC.
Publish Date	2022-09-22 06:32
Citation	Aguado C, Maestre UJ, Mielgo-Rubio X. Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast. World J Clin Oncol 2022; 13(9): 758-761
URL	https://www.wjgnet.com/2218-4333/full/v13/i9/758.htm
DOI	https://dx.doi.org/10.5306/wjco.v13.i9.758

Full Article (PDF)	WJCO-13-758.pdf
Full Article (Word)	WJCO-13-758.docx
Manuscript File	77472_Auto_Edited-LM.docx
Answering Reviewers	77472-Answering reviewers.pdf
Audio Core Tip	77472-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	77472-Conflict-of-interest statement.pdf
Copyright License Agreement	77472-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	77472-Language certificate.pdf
Peer-review Report	77472-Peer-review(s).pdf
Scientific Misconduct Check	77472-Bing-Liu JH-2.jpg
Scientific Misconduct Check	77472-CrossCheck.jpg
Scientific Editor Work List	77472-Scientific editor work list.pdf
CrossCheck Report	77472-CrossCheck report.pdf